GSK rolls out new DTC ads for Lovaza

Share this article:
GSK rolls out new DTC ads for Lovaza
GSK rolls out new DTC ads for Lovaza

GlaxoSmithKline launched new TV spots last week for Lovaza, a prescription omega-3 fish oil capsule indicated for the lowering of very high triglyceride levels.

TV spots, as well as the consumer print and online ads that debuted in January, emphasize the drug's natural ingredient: "Lovaza — the prescription that starts in the sea." On television, a white-coated physician handles beakers in a lab surrounded by a gigantic wall-sized aquarium.

Bernadette King, a GSK spokesperson, said the campaign targets "people at higher risk," such as Type 2 diabetics, people with high blood pressure, high cholesterol, and the overweight. "There's a big potential to educate consumers on high triglycerides," she said.

King hastened to add that Lovaza is not indicated for the prevention of cardiovascular events. The campaign is geared toward reducing high triglyceride levels and building awareness around the disease, she said. "We hope it will promote patient-doctor dialogues, which should be the focus of any DTC campaign," said King

McCann HumanCare created the DTC work for Lovaza, and imc2 worked on digital and online elements, said King.

Online content at Lovaza.com includes patient testimonials and a "Put Lovaza to the Test" game for visitors. A coupon on the website offers $20 off 12 refills of the drug, which costs around $160 for a month supply, according to Consumer Reports.
Share this article:

Email Newsletters

More in News

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

Executives urge analysts to focus on the company's long-term potential.

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union